Postgraduate Course, Parts 1-4: The Future Is Here - Practicing Hepatology in 2024 (Ticketed)

Description

With rapid advancements in digital health, big data, and artificial intelligence, the practice of hepatology is undergoing a transformative evolution. This 4-session course provides comprehensive updates on crucially important diagnostics and therapeutics as they relate to persons with liver disease with a focus on innovation and changing paradigms. Each session is practical and interactive, featuring 4 lectures followed by a question-and-answer discussion with the panel.
 
Session 1 (8:00 AM - 9:30 AM): A Day in the Life of the Modern Hepatologist—Steatotic Liver Diseases
This session addresses the most common liver diseases: metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD). Speakers address how to risk-stratify persons with MASLD using modern techniques available now or in the future. Presenters also discuss practical approaches to MASLD treatment, including both approved and pipeline therapeutics, along with novel treatments for obesity, including pharmaceutical, surgical, and endoscopic interventions. The changing role of hepatology clinicians and practical approaches for the treatment of alcohol use disorders are also explored.

Session 2 (11:00 AM - 12:30 PM): Liver Cancers—New Solutions for Old Problems
Primary liver cancer remains one of the most lethal cancers worldwide. However, new hope arises from novel methods for risk stratification and treatment. This session reviews novel methods for risk stratification and surveillance, including electronic health record (EHR) risk stratification, novel imaging biomarkers, and new imaging modalities. Evolving paradigms for cholangiocarcinoma are addressed along with new treatments for HCC. The role of hepatology specialists in systemic therapy is also debated.

Session 3 (2:00 AM - 3:30 PM): Updates for the Liver Clinic in 2024
This session covers new developments in hereditary liver diseases, pediatric liver diseases, autoimmune liver diseases, and viral hepatitis. Topics addressed include new developments in Wilson disease, hemochromatosis, and alpha-1 antitrypsin deficiency; pediatric liver diseases updates; new developments in autoimmune liver diseases; and future directions for HBV/HDV coinfection therapy.
 
Session 4 (4:00 PM - 5:30 PM): Paradigm Shifts in Hepatology
Focusing on paradigm shifts in the care of persons with liver disease, this session explores the use of digital information to improve health disparities, changing approaches to portal hypertension treatment, and new technological advances to enhance the organ donor pool. The session concludes with a keynote lecture addressing how to harness the potential of our digital future.